Axsome spotlights mental health treatments
NEW YORK — Axsome Therapeutics, Inc.(NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, announced it is recognizing Mental Illness Awareness Week (MIAW) alongside the national mental health advocacy community including the National Alliance on Mental Illness (NAMI). This year’s theme for MIAW is “Building Community: Supporting Mental Well-being Together,” to highlight the importance of meaningful connections, the value of grassroots advocacy, and impact of local action to strengthen mental health support within communities.
“Mental health matters every day. But during MIAW, we come together to raise awareness, support one another, and build stronger communities. NAMI is dedicated to providing advocacy, education, support, and public awareness so that all individuals and families affected by mental illness can build better lives,” said Jessica Edwards, NAMI’s Chief Development Officer.
NAMI’s Community Health Equity Alliance advances mental health equity by uniting community-based organizations, thought leaders, and NAMI’s local affiliates to improve care for Black/African ancestry adults living with serious mental illness.
Dr. Herriot r. Tabuteau has served as our founder, Chief Executive Officer, and Chairman of our board of directors since our founding in January 2012. Prior to founding our company, Dr. Tabuteau was a Senior Analyst and Partner at Healthco/S.A.C. Capital (now known as HealthCor) where he was responsible for the biotechnology, genomics, and instrumentation portfolios. Previously, Dr. Tabuteau was the healthcare analyst at Kingdon Capital. Prior to that position, Dr. Tabuteau was a Senior Research Analyst at Banc of America Securities covering the hospital supplies sector. Prior to Banc of America, Dr. Tabuteau was part of the healthcare investment banking group at Goldman Sachs. The Haitian-boren Dr. Tabuteau earned his M.D. from Yale University School of Medicine and his Bachelor of Arts in molecular biology and biochemistry from Wesleyan University.
Mental health conditions continue to have a significant impact in the United States where more than 1 in 5 adults experience mental illness each year.1 In addition, more than 1 in 7 youth, ages 6-17, experience a mental health condition each year.2 Nearly 90% of people living with depression report at least some difficulty with work, home or social activities due to their symptoms, contributing to the challenge of keeping up with day-to-day life, underscoring the impact that depression has in the U.S.3
Since its founding, Axsome has been committed to the millions of individuals living with mental health conditions, their loved ones, and the healthcare providers involved in their wellness journeys. In support of its mission to deliver transformative medicines for people impacted by CNS conditions, Axsome partners with leading national and global advocacy organizations on the shared goal of strengthening communities, and to help reduce stigma, raise awareness, and provide valuable resources and support to those affected by mental health challenges.
With a $6 billion market cap in October 2025, Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States
